The EDC3 Knockout HeLa Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from HeLa cells, designed to disrupt the EDC3 gene. This pooled knockout model provides a heterogeneous loss-of-function system for studying mRNA decapping and turnover without clonal selection. The polyclonal format preserves genetic diversity, enabling robust analysis of EDC3-dependent processes across a population of edited cells.
HeLa cells are an immortalized cell line originating from a cervical adenocarcinoma, widely used in biomedical research due to their robust growth and extensive characterization. As an epithelial cancer cell line, HeLa offers a tractable model for investigating post-transcriptional gene regulation in a cancerous context, particularly in pathways involving mRNA stability and translational control.
EDC3 encodes an enhancer of mRNA decapping that functions as a scaffolding protein within cytoplasmic processing bodies (P-bodies). It interacts directly with DCP1A and DCP2 to stimulate the decapping complex, and cooperates with EDC4, DDX6, the LSm1-7 complex, and PATL1 to promote removal of the 5′ 7-methylguanosine cap. This activity commits mRNAs to 5′-to-3′ degradation by XRN1. EDC3 is regulated by stress signals such as arsenite and heat shock, as well as miRNA pathway activation, and it contributes to nonsense-mediated decay, thereby linking environmental cues to mRNA fate.
In the HeLa cervical cancer background, disruption of EDC3 perturbs P-body assembly and mRNA decay kinetics, potentially altering the expression of oncogenes and tumor suppressors whose transcripts are subject to decapping-dependent regulation. This knockout model is particularly relevant for investigating how aberrant mRNA turnover contributes to cancer cell proliferation, survival, and drug response, given the frequent dysregulation of RNA-binding proteins and decapping factors in malignancies.
The EDC3 Knockout HeLa Polyclonal Cells are suitable for a range of applications including measurement of mRNA stability via actinomycin D chase, genome-wide transcript profiling by RNA-seq, and quantitative analysis of decapping targets using RT-qPCR. The cells can be employed to assess P-body dynamics through immunofluorescence detection of markers such as DDX6 or DCP1A, and to validate small-molecule modulators of mRNA decay in drug sensitivity assays. Co-immunoprecipitation experiments can probe altered protein interactions within the decapping complex. For further details on this product, please contact Ascent Research.
